Drug intelligence / Profile preview

gemcitabine + interleukin-2 + oxaliplatin

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
Administration: Intravenous, Subcutaneous

Overview

A chemotherapy combination regimen consisting of gemcitabine, oxaliplatin, and interleukin-2. This combination leverages the cytotoxic effects of gemcitabine and oxaliplatin along with the immunomodulatory properties of interleukin-2. The regimen has been studied in various cancers including pancreatic adenocarcinoma and lymphomas. The GOLFIG regimen is an expanded version that includes additional components (levofolinate, 5-fluorouracil, and granulocyte-macrophage colony-stimulating factor).

Other names: GEMOX-IL2GEMOX-IL-2GEMOX-IL 2

Targets

IL-2R (Interleukin-2/interleukin-15 receptor complex)DNA polymerase familyDNARNR (Ribonucleotide reductase)

Beyond the preview

Go deeper on gemcitabine + interleukin-2 + oxaliplatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gemcitabine + interleukin-2 + oxaliplatin.

Explore the full profile